Cancerdrugs-Suchmaschine

Geben Sie hier Ihre Suchbegriffe ein,
z.B. Substanznamen, Nebenwirkungen,
Begleitmedikation etc.
Gross- und Kleinschreibung
beachten; keine Sonderzeichen.
<<< zurück Startseite Meldung unerwünschter Wirkungen Kontakt

Referenzen

Moderne orale Substanzen A-Z

  1. Arzneimittelkompendium der Schweiz
  2. Pleyer L, Greil R. Arzneimittelprofil Dasatinib. Medizin Medien Austria. November 2007
  3. Li J, Uhao M, He P et al. Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clin Canc Res 2007; 13: 3731-3737
  4. Eickhoff C, Schulz M. Imatinib, ein Tyrosinkinase-Inhibitor. Pharmazeutische Zeitschrift online 2003. Ausgabe 19
  5. Rumpold H, Gastl G, Wolf D. Arzneimittelprofil Nilotinib. Medizin Medien Austria. März 2008
  6. Bhojani N et al. Toxicities Associated with the Administration of Sorafenib, Sunitinib and Temsirolimus and Their Management. 2008; 53: 917-930
  7. Greil R, Micksche M. Arzneimittelprofil Sorafenib. Medizin Medien Austria. Dezember 2006
  8. Schmidinger M, Loidl W. Arzneimittelprofil Sunitinib. Medizin Medien Austria. April 2007
  9. Übersetzung der australischen Produktinformation zu Thalidomide Pharmion 50 mg Hartkapseln. Version 1, 23. August 2004
  10. Europäische Fachinformation Thalidomide: http://www.emea.europa.eu/humandocs/Humans/EPAR/thalidomidecelgene/thalidomidecelgene.htm
  11. Marty M, Fumoleau P, Adenis A et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12: 1643-1649, 2001
  12. Nguyen L, Tranchand B, Puozzo C et al. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trial. Clin Pharmacol. 53, 459-468.
  13. Yeh ETH, et al. Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management J Am Coll Cardiol 2009; 53: 2231–47
  14. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002;13:484 –5.
  15. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134: 75– 82.
  16. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005; 41: 1542– 6.
  17. Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol 2008; 6 :41– 8.
  18. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27: 23–44.
  19. Cardinale D, Colombo A, Colombo N. Acute coronary syndrome induced by oral capecitabine. Can J Cardiol 2006; 22: 251–3.
  20. Singer M. Cardiotoxicity and capecitabine: a case report. Clin J Oncol Nurs 2003; 7: 72–5.
  21. Bertolini A, Flumano M, Fusco O, et al. Acute cardiotoxicity during capecitabine treatment: a case report [in Italian]. Tumori 2001; 87: 200–6.
  22. Schnetzler B, Popova N, Collao Lamb C, Sappino AP. Coronary spasm induced by capecitabine. Ann Oncol 2001; 12: 723– 4.
  23. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13: 797– 801.
  24. Arbea L, Coma-Canella I, Martinez-Monge R, Garcia-Foncillas J. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. World J Gastroenterol 2007; 13: 2135–7.
  25. Sestito A, Sgueglia GA, Pozzo C, et al. Coronary artery spasm induced by capecitabine. J Cardiovasc Med (Hagerstown) 2006; 7: 136–8.
  26. Papadopoulos CA, Wilson H. Capecitabine-associated coronary vasospasm: a case report. Emerg Med J 2008; 25: 307–9.
  27. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.
  28. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994 May 28;343(8909):1318-21.
  29. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003 Nov;18(11):937-47.
  30. Diesing D, Friedrich M, von Otte S. Nebenwirkungen der endokrinen Therapie beim Mammakarzinom. Gynäkologische Endokrinologie 2005 (3):91-96.
  31. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest. 2010 Feb;137(2):456-9.
  32. Aparicio G, Calvo MB, Medina V, Fernandez O, Jimenez P, Lema M, et al. Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol. 2009 Aug;11(8):499-510.
  33. Otton J, Hayward CS, Keogh AM, Glanville AR, Macdonald PS. Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant. 2009 Jan;28(1):104-6.
  34. Rodriguez-Moreno A, Ridao N, Garcia-Ledesma P, Calvo N, Perez-Flores I, Marques M, et al. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc. 2009 Jul-Aug;41(6):2163-5.
  35. Exposito V, Vasquez de Prada JA, Gomez-Roman JJ, Gonzalez-Vilchez F, Llano-Cardenal M, Garcia-Camarero T, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. Journal of Heart and Lung Transplantation. 2008;27(7):797-800.
  36. David S, Kumpers P, Shin H, Haller H, Fliser D. Everolimus-associated interstitial pneumonitis in apatient with a heart transplant. Nephrology Dialysis Transplantation 2007; 22: 3363-3364.
  37. Tyverb EPAR Procuct Information
  38. Tykerb (Lapatinib) U.S. Prescribing Information
  39. Yeh ETH, Bickford CL. Cardiovascular Complications of Cancer Therapy:Incidence, Pathogenesis, Diagnosis, and Management. J Am Coll Cardiol 2009;53:2231–47.
  40. Mellor HR, Bell AR, Valentin J-P et al. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. (2011) 120 (1): 14-32.
  41. Je, YMS et al.: Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. The Lancet Oncology 2009, 10(10):967-974
  42. Hamnvik OP, Larsen PR, Marqusee E.
    J Natl Cancer Inst. 2011 Nov 2;103(21):1572-87. Epub 2011 Oct 18
  43. Zelboraf Drug Approval Package, Medical Review Nov 30, 2011
  44. Torben K. Becker; Sai-Ching J. Yeung. Drug-induced QT interval prolongation in cancer Patients. Oncol Rev 2010
  45. FDA Safety Announcement 10-11-2011
  46. Zelboraf Full Prescribing Information. Reference ID 3001518

Interaktionen

  1. Arzneimittelkompendium der Schweiz
  2. Kämmerer W. Klinisch relevante pharmakokinetische Interaktionen von und mit Zytostatika. Arzneimitteltherapie 2008; 26. Jahrgang, Heft 2: 51-61
  3. Pleyer L, Greil R. Arzneimittelprofil Dasatinib. Medizin Medien Austria. November 2007
  4. Li J, Uhao M, He P et al. Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clin Canc Res 2007; 13: 3731-3737
  5. Eickhoff C, Schulz M. Imatinib, ein Tyrosinkinase-Inhibitor. Pharmazeutische Zeitschrift online 2003. Ausgabe 19
  6. Drucker BJ, Sawyers CL, Capdeville R et al. Chronic myeloid leukemia. Hematology 2001: 87-112
  7. Rumpold H, Gastl G, Wolf D. Arzneimittelprofil Nilotinib. Medizin Medien Austria. März 2008
  8. Greil R, Micksche M. Arzneimittelprofil Sorafenib. Medizin Medien Austria. Dezember 2006
  9. Schmidinger M, Loidl W. Arzneimittelprofil Sunitinib. Medizin Medien Austria. April 2007
  10. Übersetzung der „Product Information” (Produktinformation) zu Thalidomide Pharmion 50 mg Hartkapseln, Version 1, 23. August 2004
  11. Thalomid (thalidomide) Capsules. Revised Package Insert, 15 July 1998
  12. Fattinger K, Roos M, Vergeres P et al. Epidemiology of drug exposure and adverse drug reaction in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 499: 158-167
  13. Zoppi M, Braunschweig S, Kuenzi UP et al. Incidence of lethal adverse drug reactions in the comprehensive hospital drug monitoring, a 20-year survey, 1974-1993, based on the data of Berne/St. Gallen. Eur J Clin Pharmacol 2000; 56: 427-430
  14. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004; 5: 489-496
  15. Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minmized? Crit Rev Oncol Hematol 2005; 55: 117-142
  16. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998; 45: 539-544
  17. Lam MSH, Ignoffo RJ. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Practice 2003; 9: 45-85
  18. Kämmerer W. Klinisch relevante pharmakokinetische Interaktionen von und mit Zytostatika. Arzneimitteltherapie 2008; 26. Jahrgang, Heft 2: 51-61
  19. Benet LZ, Hoener BA. Changes in plasma protein bindings have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-121
  20. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450-2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005: 56-63
  21. Zagermann-Muncke P. Wenn Arzneistoffe die Transportproteine beeinflussen. PZ Pharmazeutische Zeitung online 2006; 50
  22. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000; 97: 3473-3478
  23. Marchetti S, Mazzanti R, Beijnen J H et al. Concise review: Clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist 2007; 12: 927-941
  24. Marty M, Fumoleau P, Adenis A et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12: 1643-1649, 2001
  25. Nguyen L, Tranchand B, Puozzo C et al. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trial. Clin Pharmacol. 53, 459-468.

Unerwünschte Wirkungen und Behandlungsvorschläge

  1. Bhojani N et al. Toxicities Associated with the Administration of Sorafenib, Sunitinib and Temsirolimus and Their Management. 2008; 53: 917-930
  2. Wood LS. Managing the side effects of sorafenib and sunitinib. Community Oncology, Sept. 2006; 3: 558-562
  3. Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007; 30: 519-524
  4. Négrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Canc 2007; Supp 5. No. 7: 12-19
  5. Kollmannsberger C, Soulieres D, Wong R et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Ass J 2007; 1: 41-54
  6. Cancer-Related Fatigue. NCCN Practice Guidelines in Oncology. V. 1. 2008
  7. Wilson KG, Chochinov HM, Skirko MG et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 2007; 33: 118-129
  8. NCCN Practice Guidelines in Oncology
  9. Horowitz JR, Rivard A, van der Zee R et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997; 17: 2793-2800
  10. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 24: 1329-1331
  11. Link H. Anämie bei Krebs. Diagnostik, Therapie, Transfusionen, Erythropoese stimulierende Agentien, Eisensubstitution. Onkologe 2009; 15: 129-141
  12. Auerbach M, Silberstein PS, Webb T et al. Darbepoetin alfa (da) 500 mcg or 300 mcg once every three weeks (q3w) with or without iron in patients (pts) with chemotherapy-induced anemia. Ann Oncol 2008; Volume 19, Supplement 8
  13. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307
  14. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-1618
  15. Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-632
  16. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242
  17. Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008; 26: 1619-1625
  18. Schmidinger M, Loidl W. Arzneimittelprofil Sunitinib. Medizin Medien Austria. April 2007
  19. Benson AB, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918-26
  20. Schmidinger M. Oncology Update Symposium: Krebsmanagement in der modernen Onkologie. Zürich 11. September 2008
  21. Ginger (Zingiber officinale Roscoe)
  22. Festa RD, Kearney P, Rosenbau IR et al. Nutrition Issues
  23. http://www.palliativ-luzern.ch/de/04_ratgeber/empfehlungen-fuer-fachpersonen
  24. Beglinger C, Bauerfeind F, Bollier AM et al. Obstipation: Wichtige Triagefunktion der Apotheker. PharmaJournal 2008; 12/6: 5-10
  25. OFSP (Office fédéral de la santé publique)
  26. Robert C, Soria JC, Spatu A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500
  27. Staehler M, Haseke N, Schöppler G et al. Antiangiogenetische Therapie beim Nierenzellkarzinom. Management der Nebenwirkungen. Urologe 2006; 45: 1333-1344
  28. Hand-Foot Syndrome or Palmar-Plantar Erythrodysesthesia
  29. Kamba T and McDonald DM. British Journal of Cancer 2007 (96): 1788-1795
  30. Caravatti M, Kleinert B, Michel BA. Konservative Therapie lumbaler Rückenschmerzen. Schweiz Med Forum 2001; 9: 209-212
  31. Honkaniemi J, Kahara V, Dastidar P, Latvala M, Hietaharju A, Salonen T, Keskinen L, Ollikainen J, Vahamaki L, Kellokumpu-Lehtinen P, Frey H. Reversible posterior leukoencephalopathy after combination chemotherapy. Neuroradiology 2000; 42: 895-899
  32. Sanchez-Carpintero R, Narbona J, Lopez de Mesa R, Arbizu J, Sierrasesumaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 2001; 24: 145-148
  33. Briganti C, Caulo M, Notturno F, Tartaro A, Uncini A. Asymptomatic spinal cord involvement in posterior reversible encephalopathy syndrome. Neurology. 2009 Nov 3;73(18):1507-8. No abstract available.
  34. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):1038-48.
  35. Arbeitsgruppe für Herzinsuffizienz der Schweizerischen Gesellschaft für Kardiologie. Empfehlungen zur Diagnose und Behandlung der chronischen Herzinsuffizienz . SAEZ 2002;83(24):1233-1242.
  36. Zbinden S, Bühlmann M, Aebi S, Suter T. Kardiovaskuläre Nebenwirkungen der modernen Medikamentösen Krebstherapie. Schweiz Med Forum 2010;10(8):143-147
  37. Coombes, R.C., et al., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med, 2004. 350(11): p. 1081-92.
  38. Goss, P.E., et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med, 2003. 349(19): p. 1793-802.
  39. Buzdar, A., et al., Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol, 2001. 19(14): p. 3357-66.
  40. Richette, P., M. Corvol, and T. Bardin, Estrogens, cartilage, and osteoarthritis. Joint Bone Spine, 2003. 70(4): p. 257-62.
  41. Burstein, H.J., Aromatase inhibitor-associated arthralgia syndrome. Breast, 2007. 16(3): p. 223-34.
  42. Cuzick, J., et al., Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol, 2008. 9(12): p. 1143-8.
  43. Thorne, C., Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol, 2007. 14 Suppl 1: p. S11-9.
  44. Presant, C.A., et al., Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer, 2007. 7(10): p. 775-8.
  45. Mao, J.J., et al., Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors. Integr Cancer Ther, 2009. 8(2): p. 123-9.
  46. Khan, Q.J., et al., Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat, 2010. 119(1): p. 111-8.
  47. Khan, Q.J., A.P. O'Dea, and P. Sharma, Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol, 2010. 2010.
  48. Monnier, A., Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol, 2007. 18 Suppl 8: p. viii36-44.
  49. Hong, S., et al., The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. J Gen Intern Med, 2009. 24 Suppl 2: p. S383-8.
  50. Hickey, M., et al., Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol, 2008. 19(10): p. 1669-80.
  51. Monnier, A., Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol, 2007. 18 Suppl 8: p. viii36-44.
  52. Whiteman, M.K., et al., Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol, 2003. 101(2): p. 264-72.
  53. Thurston, R.C., et al., Physical activity and risk of vasomotor symptoms in women with and without a history of depression: results from the Harvard Study of Moods and Cycles. Menopause, 2006. 13(4): p. 553-60.
  54. Milne, H.M., et al., Association between physical activity and quality of life among Western Australian breast cancer survivors. Psychooncology, 2007. 16(12): p. 1059-68.
  55. Barton, D.L., et al., Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol, 1998. 16(2): p. 495-500.
  56. Hirata, J.D., et al., Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril, 1997. 68(6): p. 981-6.
  57. Jacobson, J.S., et al., Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol, 2001. 19(10): p. 2739-45.
  58. Penotti, M., et al., Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril, 2003. 79(5): p. 1112-7.
  59. Baber, R.J., et al., Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric, 1999. 2(2): p. 85-92.
  60. Irvin, J.H., et al., The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol, 1996. 17(4): p. 202-7.
  61. Elkins, G., et al., Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors. Psychooncology, 2007. 16(5): p. 487-92.
  62. Mom, C.H., et al., Hot flushes in breast cancer patients. Crit Rev Oncol Hematol, 2006. 57(1): p. 63-77.
  63. Nelson, H.D., et al., Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA, 2006. 295(17): p. 2057-71.
  64. Goldberg, R.M., et al., Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol, 1994. 12(1): p. 155-8.

Red Flags

  1. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.
  2. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994 May 28;343(8909):1318-21.
  3. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003 Nov;18(11):937-47.
  4. Diesing D, Friedrich M, von Otte S. Nebenwirkungen der endokrinen Therapie beim Mammakarzinom. Gynäkologische Endokrinologie 2005 (3):91-96.
  5. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest. 2010 Feb;137(2):456-9.
  6. Aparicio G, Calvo MB, Medina V, Fernandez O, Jimenez P, Lema M, et al. Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol. 2009 Aug;11(8):499-510.
  7. Otton J, Hayward CS, Keogh AM, Glanville AR, Macdonald PS. Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant. 2009 Jan;28(1):104-6.
  8. Rodriguez-Moreno A, Ridao N, Garcia-Ledesma P, Calvo N, Perez-Flores I, Marques M, et al. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc. 2009 Jul-Aug;41(6):2163-5.
  9. Exposito V, Vasquez de Prada JA, Gomez-Roman JJ, Gonzalez-Vilchez F, Llano-Cardenal M, Garcia-Camarero T, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. Journal of Heart and Lung Transplantation. 2008;27(7):797-800.
© Cancerdrugs GmbH, last update 08.02.2012.
Wichtiger Hinweis: Diese Informationen sind ausschliesslich für medizinische Fachpersonen
bestimmt. Konsultieren Sie bitte vor einer Verschreibung die vollständige Fachinformation. Nutzungsbestimmungen.

Platinum

Gold


Silber




Weitere Sponsoren